Q-omics provides the consensus-scored ACNATP profile across patient tissues and cancer cell-line models. ACNATP expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACNATP is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, ACNATP RNA expression shows 5,951 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LIHC, and TGCT as cancer lineages where ACNATP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACNATP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACNATP survival associations across molecular data types. ACNATP RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACNATP RNA expression–survival associations across cancer types. High ACNATP expression shows unfavorable associations in KIRC, ACC, KICH, UVM and COAD, but favorable associations in LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACNATP RNA expression.
This table summarizes ACNATP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ACNATP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACNATP shows lower tumor expression in KIRP and STAD and higher tumor expression in LIHC, COAD, LUSC and LUAD. The LIHC box plot shows higher ACNATP RNA expression in tumor versus normal tissue (log2 FC = +0.360, t-test p < 0.001).
This table shows molecular features associated with ACNATP in patient tissues and cancer cell lines. In patient samples, ACNATP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
